Pristiq effexor difference

Home >> Drug Vs. Friend >> Pristiq vs Effexor: Differences, Similarities & Which is Best for You

Drug Vs. Friend

Drug Overview and Key Differences | Conditions of treatment | Efficiency | Insurance coverage and cost comparison | Side effects | Drug Interactions | Warnings | FAQ

More than 16 million American adults have depression (major depressive disorder). Pristiq and Effexor are two popular medications designed to treat depression. state of mental health. Effexor XR (Extended Edition) also treats Generalized Anxiety Disorder, Panic Disorder and Social Anxiety. Both drugs are approved by the US Food and Drug Administration (FDA). Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer, makes both drugs in proprietary forms. nine0005

Pristiq and Effexor belong to a group of drugs called SNRIs (serotonin and norepinephrine reuptake inhibitors). They work by regulating the reuptake of the neurotransmitters serotonin and norepinephrine in the CNS (central nervous system), thereby improving symptoms of depression.

Note that the generic name for Pristika is desvenlafaxine and the generic name for Effexor is venlafaxine. These drugs are very similar. When the effexor (venlafaxine) is metabolized, it is converted to the active metabolite, desvenlafaxine. nine0005

Although Pristiq and Effexor are SNRIs, they have some differences which we will describe below.

What are the main differences between Pristiq and Effexor?

Pristiq and Effexor are SNRI antidepressants available in branded and generic forms. Both drugs are approved for use in adults.

Pristiq is available as an extended edition tablet. Dosage may vary, but the standard dose is 50 mg per day.

Effexor is available in tablet form, as well as extended release capsules and extended release tablets. A typical dose is 75 or 150 mg per day (XR formulation). nine0042 Desvenlafaxine succinate (desvenlafaxine) Venlafaxine hydrochloride (venlafaxine) What form(s) does the drug come in? Tablet (extended release) Tablets, extended release capsules, extended release tablets What is the standard dosage? 50 mg per day Varies: typical dose is 75 or 150 mg XR per day. nine0045 How long does a typical treatment take? Varies Varies Who usually takes this medicine? Adults Adults

Want the best price on Pristiq?

Sign up for Pristiq Price Alerts and be notified when the price changes!

Receive price alerts

Conditions treated by Pristiq and Effexor

Pristiq (what is Pristiq?) Indicated for the treatment of major depressive disorder (MDD) in adults. Sometimes Pristiq is prescribed. not intended for other purposes.

Effexor (immediate release) is indicated for the treatment of major depressive disorder. Effexor XR (what is Effexor?) is indicated for major depressive disorder, generalized anxiety disorder, social anxiety disorder and panic disorder.

Is Pristiq or Effexor more effective?

A meta-analysis examined the safety and efficacy of Pristiq and Effexor. The researchers concluded that both drugs were similar in terms of effectiveness in treating depression as well as side effects. However, patients taking Pristiq experienced less nausea than patients taking Effexor. nine0005

Consult your physician for medical advice. Only your healthcare provider can determine which medicine is best for you based on your medical condition and medical history, as well as any medicines you are taking that may interact with Pristiq or Effexor.

Get a pharmacy discount card

Pristiq and Effexor coverage and cost comparison

Insurance plans and Medicare Part D usually cover Pristiq. The regular price for a typical prescription for generic 30.50 mg tablets is around $380. A free SingleCare card can bring the price down to under $60. nine0012 Plans and Medicare Part D usually cover Effexor XR (the most commonly prescribed type of Effexor). The regular price for a typical prescription for 30 150mg capsules is about $140. You can use the free SingleCare card to bring the price down to about $15.

Because insurance plans vary and are subject to change, contact your health plan for up-to-date coverage information.

* COMMUNITIONS FOR EFFEXOR XR, the most often prescribed EFFEXOR drug. nine0012 Source: DailyMed (Pristiq), DailyMed (Effexor XR)

Drug Interactions Pristiq vs Effexor

The use of SNRI antidepressants with MAO inhibitors may increase the risk of serotonin syndrome, which can be life-threatening. Pristiq or Effexor must be separated from the MAOI for seven to 14 days, depending on which drug was discontinued first. Pristiq or Effexor should not be taken with other serotonin-raising medications such as other SNRI or SSRI antidepressants, migraine triptans, and opioids for the same reason. In addition, the dextromethorphan cough found in Robitussin-DM as well as many other cough and cold products should be avoided as it can also cause serotonin syndrome when combined with Pristiq or Effexor. nine0005

Other drugs that may interact with Pristiq or Effexor include NSAIDs (non-steroidal anti-inflammatory drugs) such as aspirin or ibuprofen and anticoagulants (blood thinners) such as warfarin. Avoid drinking alcohol while taking Pristiq or Effexor.

If Pristiq is taken with a drug that is metabolized by the cytochrome P 2D6 enzyme, the level of the other drug may reach too high and become toxic. Dosage adjustment may be required. The effexor does not have this interaction. nine0005

Other warnings include:

• Pristiq and Effexor are not approved for pediatric patients.
• Serotonin syndrome is a serious, life-threatening emergency caused by the accumulation of too much serotonin. Patients taking Pristiq or Effexor should be closely monitored for signs and symptoms of serotonin syndrome such as hallucinations, seizures, changes in blood pressure and agitation. Patients should seek emergency medical attention if any of these symptoms occur. Patients taking other drugs that increase serotonin levels (triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, dextromethorphan, amphetamines, St. John's wort and MAOIs) have a higher risk of developing serotonin syndrome. nine0646
• Pristiq or Effexor may increase blood pressure. Check your blood pressure regularly. If you have high blood pressure or heart problems, check with your doctor before taking Pristiq or Effexor.
• SNRIs may increase the risk of bleeding. The risk is increased when taking aspirin, NSAIDs or warfarin at the same time.
• Activation of mania or hypomania may occur. In patients with bipolar disorder, antidepressants may induce a mixed/manic episode. nine0646
• Avoid or use SNRIs with caution in patients with untreated anatomically narrow angles (angle-closure glaucoma). Ask your doctor if you are at risk.
• When you stop taking Pristiq or Effexor, ask your doctor to schedule a gradual dose reduction. Abrupt discontinuation may cause withdrawal symptoms such as nausea, tremors, confusion, and convulsions. Gradually reducing the dose may help avoid these symptoms. nine0646
• Hyponatremia (low sodium levels) may occur due to syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Patients may experience headaches, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to a fall. More serious cases may occur. Patients should seek emergency care if symptoms develop and stop taking SNRIs.
• Do not drive or operate machinery until you know how Pristiq or Effexor affects you. nine0646
• Talk to your doctor about using Pristiq or Effexor if you have a history of seizures.
• Rarely, rash and allergic/systemic anaphylaxis reactions or angioedema have been reported. If you develop a rash or allergic symptoms, stop taking Pristiq or Effexor and seek medical attention immediately. Do not take Pristiq or Effexor if you are allergic to any of the ingredients.
• These drugs have been associated in rare cases of interstitial lung disease and eosinophilic pneumonia. If you are taking Pristiq or Effexor and you experience shortness of breath, cough, or chest discomfort, seek immediate medical attention. nine0646
• Pristiq or Effexor should be used during pregnancy only if the benefit to the mother outweighs the risk to the baby. Stopping the medication may cause a relapse of depression or anxiety. Therefore, patients should be assessed on an individual basis. Your healthcare provider may weigh the risks and benefits of using an SNRI during pregnancy. Newborns exposed to SNRIs in the third trimester developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. If you are already taking Pristiq or Effexor and find out you are pregnant, contact your doctor immediately. nine0646
• Pristiq: Swallow the tablet whole with water. Do not chew, crush, dissolve, or split tablets.
• Effexor XR: Swallow the capsule whole with water. Do not split, crush, chew, or place the capsule in water. Alternatively, you can open the capsule, sprinkle it on a spoonful of applesauce and swallow the mixture immediately, followed by a glass of water.

Frequently asked questions about Pristiq and Effexor

What is Pristiq?

Pristiq is an SNRI antidepressant. Pristiq treats depression in adults. The generic name is desvenlafaxine.

What is Effexor?

Effexor is also an SNRI antidepressant. Effexor treats depression in adults. Effexor XR (extended release) treats depression, social anxiety disorder, panic disorder, and generalized anxiety disorder. Effexor's generic name is venlafaxine.

Are Pristiq and Effexor the same thing? nine0124

Medicines are very similar. When Effexor is metabolized in the body, it is converted to desvenlafaxine, the active ingredient in Pristiq. The two drugs are similar but have some differences, such as dose, price, side effects, and drug interactions.

Is Pristiq or Effexor better?

Both drugs are similar in efficacy. Your healthcare provider can advise you on which drug is right for you.

Can I use Pristiq or Effexor while pregnant? nine0124

Consult your doctor. He or she will weigh the benefits of taking an antidepressant against the risk to the child. Newborns treated with certain antidepressants, including SNRIs or SSRIs (selective serotonin reuptake inhibitors such as Prozac), developed serious complications in the third trimester of pregnancy.

If you are already taking Pristiq or Effexor and find out you are pregnant, contact your OB/GYN right away. If you are breastfeeding, please also consult your OB/GYN. nine0005

Can I use Pristiq or Effexor with alcohol?

No. Pristiq or Effexor should not be taken with alcohol because the combination may increase the risk of respiratory depression (slowed breathing, lack of oxygen) and increase sedation and drowsiness, as well as impair alertness. The combination can also exacerbate anxiety and depression.

Does Pristiq help with anxiety?

Although Pristiq is only indicated for the treatment of depression, some clinicians prescribe it off-label for anxiety. However, in clinical trials, 3% of patients who took Pristiq 50 mg (recommended dose) experienced anxiety as a side effect. Some need to try different medications to see what works best. Consult with your healthcare provider for more information. nine0005

Pristiq Mood Stabilizer?

Medicines classified as mood stabilizers are commonly used to treat bipolar disorder. Pristiq is indicated for the treatment of depression. Taking Pristiq may improve your mood, but it is not classified as a mood stabilizer. Pristiq is an SNRI antidepressant.

Venlafaxine is an SNRI?

Yes. Effexor (venlafaxine) is an SNRI. Other SNRIs for depression include Pristiq (desvenlafaxine), Fetzima (levomilnacipran), and Cymbalta (duloxetine). nine0005

Top 10 drugs that will lose patent protection in the US in 2017

The expiration of blockbuster patent protection is one of the key risks for pharmaceutical companies, so it is not surprising that they seek to extend the period of exclusivity for these drugs, resorting to various methods , — expanding indications for use, studying their effect for different age groups of patients, etc. US pharmaceutical market is a tasty morsel for many pharmaceutical companies, so the loss of patent protection for blockbusters in this market may mean a decrease in sales revenue for the company. The same applies to patent disputes, the resolution of which may not benefit companies producing innovative drugs and, as a result, open the “door” to the market for generics or biosimilars. According to FiercePharma, among the originators that will lose patent protection in the US this year, the top 10 most promising in terms of their sales revenue are drugs for the treatment of multiple sclerosis, erectile dysfunction, oncopathology, etc. All of them contribute a significant contribution to the sales volume of such Big Pharma players as Eli Lilly, Pfizer, Takeda, Bristol-Myers Squibb etc.
Through joint efforts in 2016, the above top 10 managed to generate sales revenue for licensed companies in the amount of 10 billion dollars US . More details about these originators can be found in this publication.
With the entry into the generic market, innovative drugs, according to monitoring data from Dickson, may lose up to 90% of sales. The bottom line is that generics can be 80-85% cheaper than brand-name drugs. The cost of biosimilars is not so significantly different from that of innovative drugs of biological origin, and in this case the difference between their prices can differ by about 15%, but can be even more with direct long-term contracts with biosimilar manufacturers. Thus, it becomes clear that the expiration of patent protection for originators is a painful process for pharmaceutical companies in terms of income from their sales, because the demand for originators may decrease with the entry of cheap analogues into the market. Below is a list of originators that are likely to lose their US exclusivity in 2017. nine0005

Teva Pharmaceutical Industries Copaxone (glatiramer acetate)

2016 US drug revenue: $3.479 billion Patent expiration date: pending 2017
Copaxone (glatiramer acetate), for the treatment of multiple sclerosis, first received Food and Drug Administration (FDA) approval in 1996. Several years ago, Teva Pharmaceutical Industries ran into patent protection problems for this innovative drug, and to deal with it, began work on obtaining a patent for Copaxone extended release. However, it is expected that this form of release of the drug in 2017 may face competition from generics, which could potentially lead to a decrease in sales of the drug in the future. nine0005

Eli Lilly Cialis (tadalafil)

2016 US drug revenue: $1.469 billion Patent expiration date: November 2017
According to Evaluate, 2 blockbusters from Eli Lilly are expected to lose patent protection in the US in 2017 - Cialis (tadalafil) and Alimta (pemetrexide), and also Strattera (atomoxetine) and Effient (prasugrel), which are less profitable for the company than the first 2 drugs. nine0012 In 2016, US sales of Cialis (tadalafil) for erectile dysfunction were $1.469 billion. However, the entry into the generic market is expected to have a significant impact on the originator's sales revenue. According to analysts at Evaluate, sales of Cialis (tadalafil) in the US in 2022 will be only $55 million. It should be noted that this originator has already made a significant contribution to Eli Lilly's sales revenue during its market marketing of more than $17 billion. The company is fighting to extend the term of patent protection for this drug in the United States by expanding its scope in pediatrics. And this is not surprising, because, according to the company "Evaluate", the sales volume of Cialis (tadalafil) in monetary terms is about 14% of Eli Lilly's sales revenue worldwide and 16% in the United States. nine0005

Pfizer Viagra (sildenafil)

2016 US drug revenue: $1.148 billion Patent expires December 2017.
Viagra (sildenafil), a well-known erectile dysfunction drug, was approved by the FDA in 1998. In the nearly two decades since the drug was approved, Pfizer has done a lot to market this brand and its promotion among professionals. As a result, this innovative drug achieved blockbuster status, with sales in the United States in 2016, according to FiercePharma, amounting to $1.148 billion. However, due to the expiration of patent protection for Viagra (sildenafil) and the entry into the generic market, Evaluate analysts predict a decline in revenue from sales of the originator in the US from a projected $1.1 billion. in 2017 to 188 million dollars. in 2022

Takeda's Velcade (bortezomib)

2016 US drug revenue: $1.13 billion Patent expiration date: November 2017.
In 2015, a US federal court ruled that a patent that granted exclusivity to Velcade (bortezomib) until 2022 was invalid. In this regard, this anticancer drug is likely to face competition from generics in the near future. Thus, Evaluate analysts predict that Velcade (bortezomib) sales in the United States by 2022 will be $187 million. To offset the loss associated with the loss of Velcade (bortezomib) exclusivity, Takeda is making significant efforts to market new products globally. nine0005

Bristol-Myers Squibb Sustiva (efavirenz)

2016 US drug revenue: $901 million Patent expires: December 2017.
Sustiva (efavirenz) is an antiviral drug for the treatment of HIV infection. At the end of 2016, its sales in the United States amounted to $901 million, while global sales revenue reached $1.065 billion. Sustiva (efavirenz) sales revenue in the US is less than 1/20 of the company's sales revenue. Patent protection for the formula of this drug ended in 2013, and the exclusivity of the treatment method is lost in 2017. Previously, Bristol-Myers Squibb managed to extend the patent protection period for Sustiva (efavirenz) for up to 6 months by expanding its scope in the children's age group. To offset the risks associated with losing exclusivity on Sustiva (efavirenz), Bristol-Myers Squibb is making efforts to market new brands, including the cancer drug Opdivo (nivolumab). nine0005

Novartis Sandostatin LAR (octreotide)

2016 US drug revenue: $853 million Patent expires January 2017.
Sandostatin LAR (octreotide), approved in the US as early as 1998, is indicated for the treatment of acromegaly, a growth hormone disorder that affects fewer than 20,000 patients in the US each year. The drug is also prescribed to eliminate the symptoms of carcinoid tumors. Despite losing patent protection for the drug in early 2017, analysts at Evaluate predict that US revenues from Sandostatin LAR (octreotide) will continue to rise in 2017-2018. and decrease only slightly in subsequent years. nine0005

Novo Nordisk's Norditropin SimpleXx (growth hormone)

2016 US drug revenue: $642.5 million Patent expiration date: December 2017.
Norditropin SimpleXx (somatotropin) is intended for the treatment of growth disorders in children with endogenous growth hormone deficiency, chronic renal failure in children, accompanied by growth retardation, Shereshevsky-Turner syndrome, osteoporosis, immunodeficiency syndrome, accompanied by a decrease in body weight. Despite the expiration of patent protection for the drug Norditropin SimpleXx (somatotropin), in the US, according to representatives of the company "FiercePharma", it is unlikely to experience significant competition from generics in the near future thanks to its proprietary syringe pen. Growth Hormone injectable form (Norditropin SimpleXx (somatotropin)) was developed in response to the need to have a stable form of Norditropin (somatotropin) in the form of a solution, without the need to dissolve it, for simple and convenient daily injections of somatotropin. According to Evaluate analysts, it is thanks to the proprietary syringe pen that sales of Norditropin SimpleXx (growth hormone) in the United States will suffer only slightly and amount to 586 million dollars. by 2022
It is worth noting that patent protection for Norditropin SimpleXx (somatotropin) will end in 2017 not only in the US, but also in Germany, China and Japan.

Gilead Sciences Viread (tenofovir disoproxil fumarate)

2016 US drug revenue: $591 million Patent expiration date: December 2017
Tenofovir disoproxil fumarate, marketed by Gilead Sciences under the brand name Viread, belongs to a class of antiretroviral drugs known as nucleotide analog reverse transcriptase inhibitors that block reverse transcriptase, a critical viral enzyme in the virus human immunodeficiency-1 (HIV-1). The drug received FDA approval in 2001. Over time, Gilead Sciences began developing combination drugs based on tenofovir disoproxil fumarate. Thus, the blockbuster Truvada (emtricitabine + tenofovir disoproxil fumarate) entered the market. nine0012 Gilead Sciences has focused efforts on improving the formula of antiretroviral drugs in order to reduce the severity of their side effects. Thus, tenofovir alafemid was released, which today is the basis for the development of new combination drugs. Among other things, these efforts, as well as extensive research to bring to market new blockbusters for the treatment of HIV and viral hepatitis, are believed to enable Gilead Sciences to mitigate the risks associated with losing the exclusivity of Viread (tenofovir disoproxil fumarate). nine0005

Pfizer Pristiq (desfenlafaxine)

2016 US drug revenue: $578 million Patent expiration date: March 2017.
Pfizer's antidepressant Pristiq (desfenlafaxine) entered the US market in 2008, just as its predecessor, the antidepressant Effexor (venlafaxine), was approaching the end of its life in the market. . Pristiq (desfenlafaxine) was introduced as an improved Effexor (venlafaxine) formula developed by Wyeth before being acquired by Pfizer. nine0012 Pfizer had hopes that Pristiq (desfenlafaxine) would replace the blockbuster Effexor (venlafaxine), which had $2.7 billion in US sales in 2009. However, it was difficult for the new product to compete with generic Effexor (venlafaxine), and as a result, sales revenue for Pristiq (desfenlafaxine) peaked at $737 million. in 2014

Eli Lilly's Strattera (Atomoxetine)

2016 US drug revenue: $535 million Patent expiration date: May 2017
Strattera (atomoxetine) for the treatment of attention deficit hyperactivity disorder was approved by the FDA in 2002. Sales of the drug in the United States in 2016 were $535 million and worldwide sales revenue was $855 million . Analysts at Evaluate predict that due to the expiration of patent protection for the drug in May 2017, it may face competition from generics, as a result of which revenues from its sales will decrease to $64 million.

• 
  Things to help with seasonal depression
• 
  Bpd and workplace
• 
  Self care when depressed
• 
  Free depression inventory
• 
  Do you get enough sleep quiz
• 
  Cognitive restructuring psychology definition
• 
  Schizophrenia and families
• 
  How to change your attitude
• 
  Cherokee legend wolves
• 
  Feeling a connection with someone
• 
  New brain imaging technologies